Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee
- Walter P MaksymowychAffiliated withDepartment of Medicine, University of Alberta Email author
- , Anthony S RussellAffiliated withDepartment of Medicine, University of Alberta
- , Peter ChiuAffiliated withDepartment of Medicine, University of Alberta
- , Alex YanAffiliated withDepartment of Medicine, University of Alberta
- , Niall JonesAffiliated withDepartment of Medicine, University of Alberta
- , Tracey ClareAffiliated withDepartment of Radiology, University of Alberta
- , Robert GW LambertAffiliated withDepartment of Radiology, University of Alberta
Inflammation associated with synovial expression of TNFα is a recognised feature of osteoarthritis (OA), although no studies have yet reported beneficial effects of anti-TNFα therapy on clinical manifestations of inflammation in OA.
We conducted an open-label evaluation of adalimumab over 12 weeks in 20 patients with OA of the knee and evidence of effusion clinically. Inclusion criteria included daily knee pain for the month preceding study enrolment and a summed pain score of 125 to 400 mm visual analogue scale on the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain subscale. The primary outcome was the Osteoarthritis Research Society International/Outcome Measures in Rheumatology Clinical Trials (OARSI/OMERACT) response criterion at week 12. Secondary outcomes included the WOMAC pain score 20% and 50% improvement, WOMAC stiffness and function scores, patient and physician global visual analogue scale, as well as target joint swelling.
Treatment was well tolerated and completed by 17 patients with withdrawals unrelated to lack of efficacy or adverse events. By intention to treat, an OARSI/OMERACT response was recorded in 14 (70%) patients. WOMAC pain 20% and 50% responses were recorded in 14 (70%) patients and eight (40%) patients, respectively. Significant improvement was observed in mean WOMAC pain, stiffness, function, physician and patient global, as well as target joint swelling at 12 weeks (P < 0.0001 for all). After treatment discontinuation, 16 patients were available for assessment at 22 weeks and OARSI/OMERACT response compared with baseline was still evident in 10 (50%) patients.
Targeting TNFα may be of therapeutic benefit in OA and requires further evaluation in controlled trials.
- Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Arthritis Research & Therapy
- Online Date
- October 2012
- Online ISSN
- BioMed Central
- Additional Links
- Author Affiliations
- 1. Department of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta, Canada, T6G 2S2
- 2. Department of Radiology, University of Alberta, 2A2.41 Walter Mackenzie Building, Edmonton, Alberta, Canada, T6G 2B7